Microencapsulated plasmids expressing Gn and Gc glycoproteins of Rift Valley Fever virus enhance humoral immune response in mice

[1]  C. Sindato,et al.  Rift Valley , 2019, Dictionary of Geotourism.

[2]  T. Borodina,et al.  Doxorubicin-loaded biodegradable capsules: Temperature induced shrinking and study of cytotoxicity in vitro , 2019, Journal of Molecular Liquids.

[3]  L. Jouneau,et al.  A Rift Valley fever virus Gn ectodomain-based DNA vaccine induces a partial protection not improved by APC targeting , 2018, npj Vaccines.

[4]  D. S. McVey,et al.  Current Status of Rift Valley Fever Vaccine Development , 2017, Vaccines.

[5]  T. Ikegami.  Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate , 2017, Expert review of vaccines.

[6]  M. Groschup,et al.  Seroprevalence of Rift Valley fever virus in livestock during inter-epidemic period in Egypt, 2014/15 , 2017, BMC Veterinary Research.

[7]  T. Ikegami,et al.  Mutational Analysis of the Rift Valley Fever Virus Glycoprotein Precursor Proteins for Gn Protein Expression , 2016, Viruses.

[8]  C. Peters,et al.  Safety and immunogenicity of a mutagenized, live attenuated Rift Valley fever vaccine, MP-12, in a Phase 1 dose escalation and route comparison study in humans. , 2016, Vaccine.

[9]  F. Mohamed,et al.  Effect of Surfactants on Plasmid DNA Stability and Release from Poly (D,L-lactide-co-glycolide) Microspheres , 2015 .

[10]  D. S. McVey,et al.  A glycoprotein subunit vaccine elicits a strong Rift Valley fever virus neutralizing antibody response in sheep. , 2014, Vector borne and zoonotic diseases.

[11]  C. Onwulata.  Encapsulation of new active ingredients. , 2012, Annual review of food science and technology.

[12]  Nikolai Petrovsky,et al.  Technologies for enhanced efficacy of DNA vaccines , 2012, Expert review of vaccines.

[13]  G. Matyas,et al.  Phase I study of a Neisseria meningitidis liposomal vaccine containing purified outer membrane proteins and detoxified lipooligosaccharide. , 2012, Vaccine.

[14]  J. Pawęska,et al.  Molecular Epidemiology of Rift Valley Fever Virus , 2011, Emerging infectious diseases.

[15]  Shinji Makino,et al.  The Pathogenesis of Rift Valley Fever , 2011, Viruses.

[16]  J. Rusnak,et al.  Immunogenicity and safety of an inactivated Rift Valley fever vaccine in a 19-year study. , 2011, Vaccine.

[17]  N. Busquets,et al.  Rift Valley Fever: Recent Insights into Pathogenesis and Prevention , 2011, Journal of Virology.

[18]  R. Mandell,et al.  A replication-incompetent Rift Valley fever vaccine: Chimeric virus-like particles protect mice and rats against lethal challenge , 2009, Virology.

[19]  D. Holman,et al.  A Complex Adenovirus-Vectored Vaccine against Rift Valley Fever Virus Protects Mice against Lethal Infection in the Presence of Preexisting Vector Immunity , 2009, Clinical and Vaccine Immunology.

[20]  G. Sukhorukov,et al.  Biodegradable microcapsules with entrapped DNA for development of new DNA vaccines , 2009, Russian Journal of Bioorganic Chemistry.

[21]  Jagdish Singh,et al.  Preparation, characterization, cytotoxicity and transfection efficiency of poly(DL-lactide-co-glycolide) and poly(DL-lactic acid) cationic nanoparticles for controlled delivery of plasmid DNA. , 2007, International journal of pharmaceutics.

[22]  C. Peters,et al.  Rift Valley Fever Virus NSs mRNA Is Transcribed from an Incoming Anti-Viral-Sense S RNA Segment , 2005, Journal of Virology.

[23]  G. Sukhorukov,et al.  Protein encapsulation via porous CaCO3 microparticles templating. , 2004, Biomacromolecules.

[24]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[25]  L. J. Swango,et al.  Nucleic acid immunization protects dogs against challenge with virulent canine parvovirus. , 1998, Vaccine.

[26]  G. Meadors,et al.  Efficacy of a Rift Valley fever virus vaccine against an aerosol infection in rats. , 1991, Vaccine.

[27]  S. Rasheed,et al.  A simple procedure for maximum yield of high-quality plasmid DNA. , 1990, BioTechniques.

[28]  M. Pepin,et al.  Rift valley fever , 2009, Definitions.

[29]  J. Cleland.  Single-administration vaccines: controlled-release technology to mimic repeated immunizations. , 1999, Trends in biotechnology.

[30]  H. Nojima,et al.  High efficiency transformation of Escherichia coli with plasmids. , 1990, Gene.